KMPH - KMPH STOCK NEWS

KemPharm, Inc. (KMPH) has announced that research on serdexmethylphenidate (SDX), its prodrug of d-methylphenidate, will be showcased at the virtual APSARD 2022 conference from January 13-16. Two poster presentations will detail SDX's pharmacokinetic properties, highlighting its effective absorption and metabolism. Approved by the FDA in March 2021, SDX is the active ingredient in AZSTARYS®, a treatment for ADHD. The studies indicate that SDX demonstrates dose-proportional effects and consistent release of d-MPH, providing valuable insights for clinicians.

KemPharm, a specialty pharmaceutical company, announced its participation in the BIO Partnering @ JPM event from January 10-14, 2022. The event will be held virtually alongside the J.P. Morgan 40th Annual Healthcare Conference. KemPharm's management team will engage in virtual meetings with investors to discuss recent corporate achievements and the serdexmethylphenidate pipeline, including AZSTARYS, an FDA-approved ADHD treatment for patients aged six and older. Further registration details are available on their website.

KemPharm, Inc. (KMPH) announced a share repurchase program of up to $50 million, equivalent to approximately 18% of its market capitalization, effective until December 31, 2023. The decision reflects the company's strong balance sheet and belief that its shares are undervalued. The repurchase will be funded from available working capital, with the timing and number of shares dependent on market conditions. KemPharm continues to focus on advancing its product pipeline, including the commercialization of AZSTARYS, which is FDA-approved for ADHD treatment.

KemPharm, Inc. (NASDAQ: KMPH) announced positive top-line results from its Phase 1 clinical trial of serdexmethylphenidate (SDX), showing that higher doses (240-600 mg) were well-tolerated and produced dose-proportional d-MPH exposure. The study indicated targeted biological effects relevant for idiopathic hypersomnia and stimulant use disorder. The company plans to assess the commercial potential of SDX-based candidates KP1077 and KP879 and will update on expansion efforts in early Q1 2022. CEO Travis Mickle expressed optimism about SDX's unique properties and broader treatment opportunities.

KemPharm (NASDAQ: KMPH) announced its inclusion in the Nasdaq Biotechnology Index, effective December 20, 2021. This milestone enhances the company's profile among biotechnology investors.

Travis C. Mickle, CEO, stated that this addition follows their recent uplisting to the Nasdaq Global Select Market and is part of a transformative year for KemPharm. The Nasdaq Biotechnology Index tracks the performance of biotechnology and pharmaceutical securities and selects its constituents annually based on specific eligibility requirements.

KemPharm, Inc. (NASDAQ: KMPH) was awarded the 2021 David J. Gury Company of the Year by BioFlorida for its significant achievements, including the FDA approval of AZSTARYS^®, a new treatment for ADHD in patients aged six and older. This recognition highlights the company’s progress in commercialization and financial restructuring, allowing it to eliminate debt and strengthen cash reserves. The launch of AZSTARYS and the uplisting to the Nasdaq Global Select Market marks a pivotal year for KemPharm, positioning it for continued growth in 2022 and beyond.

KemPharm, Inc. (NASDAQ: KMPH) announced Richard W. Pascoe as Executive Chairman to spearhead strategic growth initiatives. The company reported Q3 2021 revenue of $2.0 million, up from $1.9 million in Q3 2020, with a net loss of $1.8 million, improving from a $3.0 million loss in the same quarter last year. AZSTARYS® was launched in July 2021, providing access to over 50 million lives. The firm elevated its stock to The Nasdaq Global Select Market and appointed Tamara A. Seymour to the Board. Total cash stood at $131.5 million as of September 30, 2021, with ongoing clinical trials for SDX expected to report results by year-end.

KemPharm, Inc. (KMPH) announced promising data on AZSTARYS® presented at the 2021 Virtual International Conference on ADHD. A pivotal study involving 150 children aged 6 to 12 showed AZSTARYS met its primary endpoint, exhibiting significantly improved attention spans compared to the placebo (p<0.001). Notably, the treatment had a rapid onset of 30 minutes and effects lasting 13 hours. Approved by the FDA in March 2021, AZSTARYS combines serdexmethylphenidate and immediate-release d-methylphenidate, marking it as a potential leading ADHD treatment.

KemPharm, a specialty pharmaceutical company, will host a conference call and live audio webcast on November 10, 2021, at 4:30 p.m. ET to discuss its third-quarter 2021 financial results. Investors must register online to access the call and will receive participant details after registration. The webcast will be available on the company's website and archived for 90 days. KemPharm focuses on developing prodrugs for conditions like ADHD and stimulant use disorder, including its FDA-approved products AZSTARYS and APADAZ.